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Role of polymorphisms of the 
inflammatory response genes and 
DC-SIGNR in genetic susceptibility to 
SARS and other infections
Key Messages
1. A genetic risk-association study involving 
more than 1200 subjects showed individuals 
homozygous for L-SIGN tandem repeats are 
less susceptible to SARS infection.
2. This was supported by in vitro binding studies 
that demonstrated homozygous L-SIGN, 
compared to heterozygous, had higher binding 
capacity for SARS coronavirus (SARS-CoV), 
with higher proteasome-dependent viral 
degradation. In contrast, homozygous L-
SIGN demonstrated lower binding capacity 
for HIV1-gp120.
3. Genetic-association studies for single 
nucleotide polymorphisms of the inflammatory 
response genes, namely TNF-α, INF-α, INF-
β, INF-γ, IL1-α, IL1-β, IL-4, IL-6 and iNOS, 
failed to show a significant association with 
SARS clinical outcomes or susceptibility.
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Introduction
The SARS outbreak had a powerful impact on both the health care system and 
the economy of Hong Kong. A proportion of unprotected people exposed to 
the virus did not develop the disease, however. It has been shown that genetic 
polymorphism is associated with vulnerability to diseases, including infectious 
diseases. DC-SIGNR (also known as L-SIGN) serves as a receptor for many 
viral and bacterial pathogens, including SARS coronavirus (SARS-CoV).1 
Heterozygous expression of polymorphic neck-region variants of L-SIGN 
might alter ligand-binding affinity2 and thus influence binding affinity and 
susceptibility to infection. The inflammatory response cytokine genes play a role 
in SARS infection and single nucleotide polymorphisms (SNPs) of these genes 
may contribute to determining susceptibility to and/or the clinical outcome of 
infection with SARS.
Aims and objectives
1. To determine whether L-SIGN neck-region tandem repeats are associated 
with susceptibility to SARS infection.
2. To determine the ligand-binding capacity of L-SIGN homo/hetero-zygotes 
with SARS-CoV and HIV1 envelop-protein (gp120).
3. To investigate the contribution of SNPs of the cytokine genes to SARS 
infection susceptibility, and their relation to clinicopathological outcomes.
Methods
This study was conducted from December 2004 to November 2006.
Study design
Case-control genetic association studies were performed to examine the 
contribution of (1) the L-SIGN neck-region tandem repeat to SARS-CoV 
infection and (2) the cytokine gene SNPs to the risk of contracting SARS and/or 
any association with clinicopathological outcomes. In-vitro binding experiments 
were performed to investigate the role of homo/hetero-zygotic L-SIGN in viral 
binding capacity for SARS-CoV and HIV1-gp120 protein.
Sample size
(1) A total of 285 SARS patients with infections confirmed by serology and/or 
reverse transcription–polymerase chain reaction for SARS were recruited. 
The controls included 380 healthy blood donors randomly recruited before the 
SARS outbreak, 290 patients from general out-patient clinics with no clinical 
history, signs or symptoms of inflammation/infection at least 2 months after 
the SARS outbreak; and 172 health care workers (HCW) who had worked 
in SARS wards but remained disease-free and were seronegative for SARS. 
Known genetic relatives were excluded from study.
(2) 309 household contact controls who had lived in households with SARS 
patients but remained unaffected by the disease and were found to be 
seronegative at the end of the outbreak were also recruited. To prevent 
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genotype and allele frequency distribution bias, the 
number of members of the same household who were 
genetically related was taken into consideration in the 
statistical analysis of genotypes. All control subjects 
were ethnically Chinese Hong Kong residents.
Study instruments
(1) L-SIGN study
Genotyping of the L-SIGN neck-region tandem repeats
L-SIGN neck-region tandem repeats were genotyped by 
amplifying exon-4 of L-SIGN using sequence specific 
primers.3 Amplified products were separated and detected 
by gel electrophoresis. Some representative cases were 
confirmed by Southern blot analysis and by direct 
sequencing.
Statistical analysis
Genetic association for heterozygote and homozygote 
genotype comparison was assessed by the χ2 test, two-
sided, and odds ratio (OR) and 95% confidence intervals 
(CIs) were used to measure the strength of the association 
in the genetic risk-association study. The Mantel-Haenzel 
test for stratified analysis was also performed. Genotyping 
results were checked for Hardy-Weinburg Equilibrium. For 
all in-vitro studies, statistical significance was calculated 
using Student’s t test.
Plasmids and cell lines
The 5 neck-region repeat (N5) of L-SIGN expressing 
plasmid was genetically engineered using DNA amplified 
from a N5-allele carrier, whereas the 7 neck-region repeats 
(N7) expressing plasmid was obtained from the AIDS 
Research Program, National Institutes of Health, US. The 
N7-L-SIGN plasmid, N5-L-SIGN plasmid or a mixture 
of N7+N5 plasmids (ratio 1:1) were transfected into CHO 
cells. L-SIGN expression was verified by immunostaining 
with L-SIGN specific antibody. Stable clones of CHO 
cells expressing N5 or N7/5-L-SIGN variants were also 
established using antibiotic selection.
Measurement of SARS-CoV ORF-1b for viral copy number
The total viral ribonucleic acid (RNA) copy number was 
determined using a quantitative reverse transcription– 
polymerase chain reaction amplifying the SARS-CoV 
ORF-1b sequence. The total copy number was calculated 
against the calibration standard curve.
Homo/hetero-zygote neck-region repeat of L-SIGN binding 
with SARS-CoV and HIV1-gp120
N5-, N7-, and N7/N5-L-SIGN transient transfectant and 
mock transfected CHO cells were pulsed with SARS-CoV. 
After incubation with the virus for 1, 24 and 48 hours, the 
cells were subjected to RNA extraction for ORF-1b viral 
copy number measurement. For proteasome inhibition 
experiment, N7-L-SIGN transfected or mock-transfected 
CHO cell pulsed with the viruses were cultured in the 
presence of proteasome inhibitors before ORF-1b copy 
number measurement.
 N5-L-SIGN, N7/N5-L-SIGN stable CHO transfectants, 
and the parental CHO cells were used to test HIV1-gp120 
binding. The percentage of cells binding with HIV1-gp120 
was detected by flow cytometry. N7-, N5-, and N7/N5-
L-SIGN transfectants were each tested three times in 
triplicate.
(2) Genetic association study of inflammatory response 
genes
SNPs selection
SNPs of nine inflammatory response cytokine genes were 
selected from the dbSNP database based on the following 
criteria: 
l	All information was based on Han Chinese genotype 
data obtained from the HapMap International Database 
(http://www.hapmap.org), available from the dbSNP of 
the National Center for Biotechnology Information.
l	SNPs in the promoter region (1.8 kb), exons (including 5’ 
untranslated regions, coding exons, and 3’ untranslated 
regions), and 3’ flanking regions (400 bp)
l	SNPs with minor allele frequency (>10%) in the Han 
Chinese population. This gave the study at least 80% 
power to detect a 2-fold risk-associated genotype in 285 
cases.
 A total of 17 SNPs were selected from eight cytokine 
genes. An appropriate SNP for TNFα could not be identified.
Genotyping of cytokine gene SNPs
Multiplex genotyping was performed using Sequenom. 
Primer design was successful for 12 out of 17 SNPs which 
could be multiplexed into two multiplex reactions: INF-α, 
INF-α, INF-β, INF-γ, INF-γ, IL1-α, IL1-α, IL1-β, IL-4, 
IL-6, iNOS, iNOS. In the genotyping assay, proper controls 
and replicates were included for quality control.
Statistical analysis
Genetic association was analysed using a two-sided χ2 test. 
A clustering logistic regression was used to adjust for genetic 
relations of HHC. The χ2 test was used for ordinal variables 
(ie intensive care unit, use of steroid, use of pulse steroid, 
use of intravenous immunoglobulin, death, and ventilation) 
whilst ANOVA and Student’s t tests were used to analyse 
continuous clinical parameters (ie alanine-aminotransferase, 
albumin, creatinine-kinase, haemoglobin, lymphocyte, 
platelet, white blood cell, globulin, lactate-dehydrogenase, 
total length of stay, total length of stay in intensive care unit, 
days from admission to start of steroid treatment, days from 
the start of steroids to the start of pulse steroids). The issue 
of multiple testing of 12 SNPs, was dealt with by using 
Bonferroni’s correction procedure to adjust for it.
Results
(1) L-SIGN study
Risk-association analysis of L-SIGN neck-region 
tandem repeat
As at least one fifth of SARS patients in Hong Kong were 
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HCW, we sub-classified our SARS patients into: (1) 67 
HCW infected during the course of duty (“HCW SARS”), 
and (2) the remaining 218 recruited from the community 
(“community SARS”).3
 When all SARS patients (HCW SARS + community 
SARS) were compared with random controls, homozygous 
individuals had a significantly lower risk association for 
SARS infection with an OR=0.706 (95% CI, 0.519-0.961; 
P=0.027, Table 1a), compared with heterozygotes. Analysis 
was performed separately in the non-HCW population 
and the HCW population. In the non-HCW population, 
community SARS versus out-patient controls gave an 
OR=0.698 (95% CI, 0.490-0.993; P=0.045, Table 1b). In 
the HCW population, HCW SARS versus HCW controls 
demonstrated an OR of 0.536 for homozygotes (95% CI, 
0.303-0.950; P=0.031; Table 1b). The stratified analysis 
between these two populations did not reveal significant 
differences (P=0.442, Table 1b), allowing us to perform 
overall association tests, yielding an overall OR=0.649 (95% 
CI, 0.481-0.876; P=0.005, Table 1b), further confirming 
that homozygosity conferred a reduced risk. As the out-
patient controls and the random controls did not differ 
from each other in their individual genotype frequencies 
or homo/hetero-zygote frequencies (P=0.737 and 0.755 
respectively, Table 2), these two controls were grouped 
together as “combined controls”. Analysis of all SARS 
patients versus combined controls again gave an OR=0.691 
for homozygotes (95% CI, 0.523-0.913; P=0.009).
Binding assay of homo/hetero-zygote L-SIGN to 
SARS-CoV and HIV1-gp120
Homozygous L-SIGN demonstrated higher SARS-CoV 
binding capacity than heterozygous L-SIGN (Fig a).3 After 
binding to L-SIGN, there was little or no viral dissociation, 
and viruses underwent degradation over time, with the 
homozygous L-SIGN more efficient than the heterozygous 
(Fig b).3 L-SIGN-mediated viral degradation could be partially 
inhibited by proteasome inhibitors (Fig c).3 In contrast, the 
homozygote L-SIGN transfectants showed less binding 
L-SIGN neck region All SARS samples Random controls
Heterozygotes† 153 (53.7%) 171 (45.0%)
Homozygotes 132 (46.3%) 209 (55.0%)
(a)
L-SIGN neck region Non-HCW population HCW population
Community SARS Out-patient controls HCW SARS HCW controls
Heterozygotes† 115 (52.8%) 127 (43.8%) 38 (56.7%) 71 (41.3%)
Homozygotes 103 (47.2%) 163 (56.2%) 29 (43.3%) 101 (58.7%)
(b)
Table 1. Statistical analysis of L-SIGN homo/hetero-zygosity and comparison of the allele and genotype frequencies*3
* The frequencies of homozygotes and heterozygotes are compared between (a) all SARS samples (health care workers [HCW] SARS + community SARS) and 
random controls, and (b) non-HCW population and HCW population for stratified analysis
† The heterozygotes are used as the reference group in comparisons in (a) and (b). All SARS samples vs random controls: χ2(df=1)=4.91, P=0.027, OR=0.706 
(95% CI=0.519-0.961). Community SARS vs out-patient controls: χ2(df=1)=4.01, P=0.045, OR=0.698 (95% CI=0.490-0.993). HCW SARS vs HCW controls: 
χ2(df=1)=4.63, P=0.031, OR=0.536 (95% CI=0.303-0.950). In (b), the Mantel-Haenzel test is performed in SARS vs controls stratified by non-HCW/HCW 
populations. Test of heterogeneity of ORs: χ2(df=1)=0.590, P=0.442. Test of overall association: χ2(df=1)=7.977, P=0.005, overall OR estimate=0.649 (95% CI, 
0.481-0.876)
L-SIGN neck 
region†
HCW SARS Community SARS HCW controls Out-patient controls‡ Random controls‡
No. % No. % No. % No. % No. %
5/5 1 1.5 8 3.7 19 11.0 14 4.8 10 2.6
5/9 2 3.0 7 3.2 3 1.7 8 2.8 15 3.9
6/5 0 0.0 3 1.4 7 4.1 2 0.7 4 1.0
6/6 0 0.0 1 0.5 0 0.0 0 0.0 2 0.5
6/9 1 1.5 3 1.4 1 0.6 3 1.0 4 1.0
7/5 16 23.9 49 22.5 25 14.5 50 17.2 63 16.6
7/6 7 10.4 12 5.5 6 3.5 25 8.6 25 6.6
7/7 27 40.3 86 39.4 76 44.2 145 50.0 191 50.3
7/8 0 0.0 0 0.0 1 0.6 0 0.0 0 0.0
7/9 12 17.9 41 18.8 28 16.3 39 13.4 60 15.8
9/9 1 1.5 8 3.7 6 3.5 4 1.4 6 1.6
Total 67 218 172 290 380
Table 2. Summary of the L-SIGN genotypes in study groups*3
* HCW SARS were health care workers infected by SARS in the course of duty; community SARS were SARS patients recruited from the community; HCW 
controls were unaffected HCW who had cared for SARS patients and were proven seronegative for SARS; Out-patient controls were individuals randomly 
recruited from out-patient clinics who had neither inflammatory nor infectious conditions; Random controls were healthy blood donors randomly recruited 
before the SARS outbreak
† Numbers of the L-SIGN neck-region tandem repeats. Hardy-Weinberg Equilibrium for HCW SARS, community SARS, HCW controls, out-patient controls and 
random controls give P values of 0.893, 0.432, <0.0001, 0.054, and 0.412, respectively
‡ Neither the genotype frequencies nor the homo/hetero-zygosity frequencies differed significantly (P=0.737 and P=0.755, respectively) between out-patient 
controls and random controls.
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to HIV1-gp120 than heterozygote transfectants (Fig d).
(2) Cytokine genes study
Genotype analysis found no significant association between 
SARS patients and HHC, nor between SARS patients and 
HCW. An analysis of clinicopathological parameters also 
found no statistically significant association after multiple-
testing adjustment.
Discussion
For our genetic-association study for L-SIGN tandem 
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Fig. SARS-CoV infection and HIV1-gp120 binding on the N7-, N5-, and N7/N5-L-SIGN/CHO transfectants*
* (a) Viral ORF-1b copy number of N7, N5, and N7/5-L-SIGN transfected CHO cells (L-SIGN/CHO), and mock transfectants (CHO), pre-
treated with anti-L-SIGN antibodies (clone 120526 and 120612, 10 μg/mL each) or isotype control antibody before being pulsed with 
1 pfu/cell SARS-CoV and incubated for 1h at 4ºC and washed.3 (b) Total viral ORF-1b copy number (cell lysates plus supernatants) 
of N7, N5 and N7/5 L-SIGN transfected CHO cells, and mock transfectants, pulsed with 1 pfu/cell SARS CoV for 1h, washed and 
subsequently incubated at 37ºC for 24 and 48 hours.3 (c) Total viral ORF-1b copy number of N7 L-SIGN transfected CHO cells, 
and mock transfectants, pulsed with 1 pfu/cell SARS CoV for 1h at 37°C, washed and subsequently incubated for 4 hours in the 
presence or absence of 10 μM MG132 or proteasome inhibitor I (Pro. Inh. 1). P<0.05 in comparison to cells treated with DMSO solvent 
control. Data are expressed as mean ± SD from triplicate, and are representative of three experiments.3 (d) L-SIGN transfectants and 
HIV1-gp120 binding experiments. Percentage of N5 and N7/5-L-SIGN transfectants that bound to HIV1-gp120. Transfectants were 
incubated in 0.5 μg HIV1-gp120 proteins (recombinant HIV1BaL-gp120 protein, an R5-topic HIV1-gp120, NIH AIDS Reagent Program, 
US) for 45 minutes at 4ºC and washed, before incubation in 5 μg/mL anti-human HIV1-gp120 (clone 2G12, NIH AIDS Reagents 
Program) for 40 minutes at 4ºC. HIV1-gp120 binding was detected by FITC-conjugated goat anti-human IgG antibody and analysed 
by BD FACSCalibur flow cytometer. N7/N5-L-SIGN transfectants showed to have significant higher binding affinity to HIV1-gp120 
than N5-L-SIGN transfectants (P=0.0022, t-test). Data are expressed as mean ± SD from triplicate, and are representative of three 
experiments
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repeats, direct comparison of SARS-infected individuals 
with their controls, together with the stratified analysis, 
showed that L-SIGN homozygotes were significantly less 
susceptible to SARS infection.3 This finding is supported 
by our observation that homozygous L-SIGN had a higher 
SARS-CoV binding capacity than heterozygous L-SIGN. 
We also showed that after binding to L-SIGN, viruses 
underwent degradation over time, with the homozygous 
more efficient than the heterozygous.3 It has been reported 
that SARS-CoV sub-genomic RNA was increased 24 
hours after infection of L-SIGN expressing cells.1 The 
increase was transient, however, and SARS-CoV antigen 
was detected by immunofluorescence staining in <1% of 
the infected L-SIGN expressing cells, which argues against 
efficient and productive viral replication mediated by L-
SIGN.1 Furthermore, L-SIGN-mediated viral degradation 
is in part proteasome-dependent because it can be partially 
inhibited by proteasome inhibitors.
 For HIV1-gp120 binding to homo/hetero-zygote 
L-SIGN transfectants, in contrast to our SARS-CoV 
findings, homozygote L-SIGN transfectants showed less 
binding to HIV1-gp120 (Fig d). The reasons for such 
differences are yet to be investigated. One possibility 
may be related to differences between the binding 
epitope of L-SIGN for HIV1-gp120 and that for SARS-
CoV. Unlike SARS-CoV, where homozygous L-SIGN 
plays a protective role, in HIV-1 infection a heterozygote 
advantage has been reported,4 with homozygous N7-
repeat carriers associated with a higher infection risk 
(17.5% high-risk HIV1-seronegative vs 28.5% HIV1-
seropositive individuals, P=0.0015), supportive of 
the findings of our HIV1-gp120 binding experiments. 
Whether the HIV1 virus is internalised and degraded on 
binding with L-SIGN as demonstrated for SARS-CoV 
remains to be investigated.
 Our genetic association study for cytokine gene SNPs 
showed no significant association with SARS infection 
susceptibility or with any clinicopathological parameters. 
Although there is a reported susceptibility to SARS 
associated with the +874A/T SNP5 being located deep within 
intron 1 of IFN-γ, its functional significance is unclear. 
Moreover, it is unlikely to be in linkage-disequilibrium with 
the promoter or 3’ flanking IFN-γ SNPs that we studied, 
which demonstrated no significant association with risk or 
clinical outcome. Although a significant association with 
SARS infection has been reported for several other genes, 
with the exception of the mannose-binding lectin gene, the 
study sample sizes were all small and need to be repeated 
using large sample sizes.
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